Healthcare Services

Neoantigen Targeted Therapies Market Future Outlook Showing Expansion Toward $21.52 Billion by 2030

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Neoantigen Targeted Therapies Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The neoantigen targeted therapies market size has shown substantial expansion in recent years. This market is anticipated to increase from $4.71 billion in 2025 to $6.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 35.8%. The growth observed in the past can be ascribed to several factors, including a scarcity of immunotherapy choices, the gradual progress in cancer vaccine development, the initial utilization of genomic sequencing, limited availability of clinical trials, and a reliance on conventional oncology treatments.

The neoantigen targeted therapies market is projected to experience substantial expansion in the coming years, with its size anticipated to reach $21.52 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 35.5%. This significant growth during the forecast period is primarily attributed to the rapid advancement of personalized cancer therapies, increased investment in genomic sequencing, the expansion of clinical research collaborations, the rising adoption of combination immunotherapies, and the growing demand for precision oncology solutions. Furthermore, major trends identified for this period include the increasing uptake of personalized cancer vaccines, the broadening of targeted immunotherapy research pipelines, a rise in clinical trials for neoantigen-based combination therapies, an escalating demand for early genetic profiling in oncology, and a surge in the development of TIL-based therapeutic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Neoantigen Targeted Therapies Market?

The expansion of precision oncology is projected to drive the growth of the neoantigen targeted therapies market moving forward. Precision oncology is a method of cancer treatment that leverages detailed genetic and molecular information regarding a patient’s tumor to guide the selection of appropriate targeted therapies. This approach employs neoantigen-targeted therapies by utilizing advanced genomic analysis to pinpoint the distinct neoantigens expressed by an individual’s cancer cells. The integration of neoantigen-targeted therapies in precision oncology signifies a strategy to address the unique genetic makeup of each patient’s tumor, providing a more personalized and effective treatment solution. As an illustration, a report titled Precision Oncology Clinical Trials & Statistics 2024, issued by Novotech in March 2024, indicated that by November 2023, twelve treatments had obtained FDA approval for specific biomarker-selected indications, with six of these also being part of the NCCN guidelines. By the close of the year, 43% of the 217 FDA-approved oncology therapies were classified under precision oncology, and 78 of these therapies featured DNA or NGS-detectable biomarkers, emphasizing the increasing prominence of biomarker-driven treatments in cancer care. Thus, the advancement of precision oncology is propelling the growth of the neoantigen targeted therapies market.

What Major Segment Divisions Exist Within The Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospitals and Clinics, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Industry Trends Are Redefining The Neoantigen Targeted Therapies Market?

Leading companies within the neoantigen targeted therapies market are adopting strategic partnership approaches to customize neoantigen vaccines and monoclonal antibody drugs, aiming to overcome existing immunotherapy challenges in treating solid tumors. Such collaborations involve companies leveraging each other’s strengths and resources to achieve mutual benefits and success. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company, collaborated with Merck & Co., Inc., another US-based pharmaceutical company, to launch mRNA-4157 (V940). This investigational individualized neoantigen therapy (INT) is designed to generate a tailored antitumor immune response based on the unique mutational signature of a patient’s tumor. mRNA-4157 (V940) functions by encoding up to 34 neoantigens to stimulate T cell responses, thereby enhancing the body’s ability to target and destroy tumor cells when combined with Merck’s immunotherapy KEYTRUDA. This combination aims to improve recurrence-free survival in patients with high-risk resected melanoma.

Which Companies Are Leading Innovation In The Neoantigen Targeted Therapies Market?

Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Read the full neoantigen targeted therapies market report here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

What Are The Leading Geographic Regions In The Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neoantigen Targeted Therapies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2026, By The Business Research Company

Malaria Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/malaria-treatment-global-market-report

Infectious Disease Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Influenza Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795